

[Back to Search Results](#)

Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)

- [Description](#)
- [Details](#)
- [Sub-Projects](#)
- [Publications](#)
- [Patents](#)
- [Outcomes](#)
- [Clinical Studies](#)
- [News and More](#)
- [History](#)
- [Similar Projects](#)

| | | | |
|---------------------------------|----------------|--|--|
| Parent Project Number | Sub-Project ID | Contact | Awardee |
| 1U54CA260582-01 | 8238 | PI/Project Leader MCALEARNEY, ANN SCHECK | Organization OHIO STATE UNIVERSITY |

Description

Abstract Text

Project Summary Responding to the **COVID-19** pandemic requires research to understand how the virus is transmitted, what types of protection are most effective, how immunity is acquired and persists, and how to best encourage people to make use of available testing and vaccines. As our understanding of serologic and viral testing opportunities and implications of test results improves, so too does our ability to provide guidance to individuals at higher risk from exposure, such as first responders and their household contacts, as well as the general public. Communication about the risks related to **COVID-19**, which is reliable and tailored to the appropriate audience, empowers individuals to make the best decisions to protect themselves. Further, when a vaccine becomes available, a thorough understanding of the barriers and perceptions related to vaccination will be critical for promoting and facilitating uptake. Translating new basic science discoveries quickly and to the appropriate audiences will thus ensure the effectiveness of initiatives that can address the spread of **COVID-19**. To that end, Project 3, "Responding to Changing Serological and Viral Information around **COVID-19** (RESPOND)," seeks to leverage information and discoveries from Projects 1 and 2, as well as from collaborations with other SeroNet Centers and Components, to develop actionable communication tools for organizations and individuals to empower them to utilize the most up-to-date information to guide their decisions. Using a mixed methods approach, including qualitative interviews and surveys in Year 1, we will first develop a baseline understanding of the communication mechanisms used by stakeholder organizations such as government and administrative health agencies, healthcare provider organizations, and employers of individuals at higher risk of exposure and disease transmission. We will also assess baseline understanding of **COVID-19** risks and testing options by individuals at higher risk, including first responders and their household contacts, as well as patients undergoing cancer treatment. In Years 2-5, we will continue our mixed methods approach through follow-up interviews and surveys incorporating new information learned Projects 1 and 2, and from SeroNet collaborators. Throughout the study we will disseminate our findings through a project website presenting communication best practices and providing tools we develop for specific stakeholder audiences, as well as the general public.

Public Health Relevance Statement

Data not available.

NIH Spending Category

- Basic Behavioral and Social Science
- Behavioral and Social Science
- Cancer
- Clinical Research
- Coronaviruses
- Emerging Infectious Diseases
- Health Services
- Immunization
- Infectious Diseases
- Prevention
- Vaccine Related

Project Terms










- Address
- Affect
- Basic Science
- Behavioral
- Bioethics Consultants
- COVID-19
- COVID-19 pandemic
- Caregivers
- Clinical
- Collaborations
- Communication
- Communication Tools
- Decision Making
- Development
- Diabetes Mellitus
- Disease
- Effectiveness
- Ens

Thank you for your feedback!

[Back to Search Results](#)

Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)

Description

-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

| | | | |
|---------------------------------|----------------|--|--|
| Parent Project Number | Sub-Project ID | Contact | Awardee |
| 1U54CA260582-01 | 8238 | PI/Project Leader MCALEARNEY, ANN SCHECK | Organization OHIO STATE UNIVERSITY |

Details

Contact PI/ Project Leader

Name
[MCALEARNEY, ANN SCHECK](#)

Title
PROFESSOR & VICE CHAIR

Contact
Ann.McAlearney@osumc.edu

Other PIs

Not Applicable

Program Official

Name

Contact
Email not available Email not available

Organization

| | | |
|-----------------------|---------------------------|------------------------|
| Name | Department Type | State Code |
| OHIO STATE UNIVERSITY | Unavailable | OH |
| City | Organization Type | Congressional District |
| COLUMBUS | Domestic Higher Education | 03 |
| Country | | |
| UNITED STATES (US) | | |

Other Information

| | | | |
|---|-------------------------------------|--------------------|-------------------|
| FOA | Administering Institutes or Centers | Project Start Date | 18-September-2020 |
| RFA-CA-20-038 | NATIONAL CANCER INSTITUTE | Project End Date | 31-August-2022 |
| Study Section | DUNS Number | Budget Start Date | 30-September-2020 |
| Special Emphasis Panel[ZCA1 GRB-L(A)] | 832127323 | Budget End Date | 29-September-2021 |
| Award Notice Date | CFDA Code | | |
| 18-September-2020 | | | |
| Fiscal Year | | | |
| 2020 | | | |

Project Funding Information for 2020

| | | |
|---------------|--------------|----------------|
| Total Funding | Direct Costs | Indirect Costs |
| \$487,663 | \$314,236 | \$173,427 |

| Year | Funding IC | FY Total Cost by |
|------|---------------------------|------------------|
| 2020 | NATIONAL CANCER INSTITUTE | \$487,663 |

NIH Categorical Spending










[Click here for more information on NIH Categorical Spending](#)

| Funding IC | FY Total Cost by IC | NIH Spending Category |
|---------------------------|---------------------|---|
| NATIONAL CANCER INSTITUTE | \$487,663 | Basic Behavioral and Social Science; Behavioral and Social Science; Cancer; Clinical Research; Coronaviruses; Emerging Infectious Diseases; Health Diseases |

Thank you for your feedback!

[Back to Search Results](#)

Description

-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)

| | | | |
|---------------------------------|----------------|--|--|
| Parent Project Number | Sub-Project ID | Contact | Awardee |
| 1U54CA260582-01 | 8238 | PI/Project Leader MCALEARNEY, ANN SCHECK | Organization OHIO STATE UNIVERSITY |

Publications

No Publications available for 1U54CA260582-01 8238

Patents

No Patents information available for 1U54CA260582-01 8238

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 1U54CA260582-01 8238

Clinical Studies

No Clinical Studies information available for 1U54CA260582-01 8238

News and More

Related News Releases

No news release information available for 1U54CA260582-01 8238

History

No Historical information available for 1U54CA260582-01 8238

Similar Projects

No Similar Projects information available for 1U54CA260582-01 8238

Thank you for your feedback!